Trial Profile

Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prasugrel (Primary) ; Aspirin
Indications Acute coronary syndromes; Angina pectoris; Ischaemia; Ischaemic heart disorders; Myocardial infarction; Stroke; Thrombosis
Focus Adverse reactions; Therapeutic Use
Acronyms PRASFIT-Practice II
Sponsors Daiichi Sankyo Company

Most Recent Events

02 Oct 2020 Final two-year follow-up results published in the Circulation Journal.
12 Nov 2019 Results of one year follow up study assessing effectiveness and safety of prasugrel were published in the Circulation Journal
24 Jan 2019 Results of interim analysis of data from case report forms (CRFs) after 3 months published in the Circulation Journal

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com